Skip to content

Author

A. Whitman

We have 2 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition

Inhibiting pan-RAS(on) RAS-GTP with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.

Michael P. East, J. Olivares-Quintero, D. Okumu et al. · 0 citations
Open access Aug 2026

Integrative Transcriptional and Chromatin Analyses Reveal Enhancer-Mediated Regulatory Programs Driving Breast Cancer Metastasis

A multi-omic resource integrating transcriptomic and chromatin accessibility profiles from estrogen receptor-positive primary breast tumors and matched liver and lung metastases obtained from the same patients, revealing new regulatory vulnerabilities that may be therapeutically exploitable.

Frances L. Heredia, Natalia Maldonado-Vazquez, H. Fogle et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.